2nd Structure-Based Drug Design Summit

With tightening budgets and increasing pressure to de-risk R AND D, pharma and biotech are shifting their focus toward smarter, more efficient drug design. Companies are investing more in enabling technologies-from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM, NMR, and X-ray crystallography-to improve rational drug design and enhance decision-making early in discovery. While AI-powered structure prediction is transforming the landscape-recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2- its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery. Cryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma - the future of structure-based drug design is here. The 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies, you’ll gain insights into how leading scientists are leveraging Cryo-EM, NMR, X-ray crystallography, and AI to solve high-value targets and drive rational drug design across small molecules, peptides, biologics, and vaccines. With coverage of design of TPDs, molecular glues, vaccines, antibodies, and mRNA, GPCRs and membrane protein targeting therapeutics plus much more! The field is evolving-don’t get left behind. Expand your network and join 80+ structural biologists, medicinal chemists, protein engineers, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.Speakers: Alexey Rak Scientific Fellow, Head of BioStructure and Biophysics Sanofi, Ann Boriack-Sjodin Executive Director and Global Head of Structural Biology Takeda Pharmaceuticals, Benoit Moreau Head of Medicinal Chemistry Remix Therapeutics, Dave Brown Senior Director, Structural Biology and Biophysics Vertex Pharmaceuticals, Douglas Whittington Executive Director, Head of Structural Biology and Biochemistry Tango Therapeutics, Inc., Elena Menichelli Director and Head of Structural Biology Arrakis Therapeutics Inc., Gabriele Corso Machine Learning and Generative Models for Structural Biology and Drug Discovery Massachusetts Institute of Technology, Grant Jensen Dean, College of Computational, Mathematical and Physical Sciences Brigham Young University, James Partridge Structural Biology Novartis, Jeremy Setser Senior Director, Structural Biology Flare Therapeutics, John Knox Vice President, Structural Chemistry and Discovery Sciences Revolution Medicines, Kirill Nadezhdin Senior Scientist AstraZeneca, Laura Silvian Senior Director, Physical Biochemistry Biogen, Lokesh Gakhar Senior Director and Head Of Structural Biology and Protein Sciences PAQ Therapeutics, Madhu Sevvana Principal Scientist, Structural Biology and Computational Biologics Design Sanofi, Melanie Adams-Cioaba Senior Director and General Manager, Pharma Thermo Fisher Scientific, Nazim Bouatta Senior Research Fellow, Systems Biology and Systems Pharmacology Harvard Medical School, Robert Englmeier Co-Founder and Chief Executive Officer CryoCloud, Seungil Han Research Fellow, Head of Cryo-EM and Structural Biology Lab Pfizer, Sonja Kuhn Head of Structural Biophysics and Computational Chemistry Research Servier, Vincent Stoll Senior Research Fellow and Director of Structural Biology Abbvie, Ximena Barros-Álvarez Senior Scientist, Membrane Protein Biochemistry, Tectonic Therapeutic, Ye Che Senior Director, Head of Structural Biology Center of Excellence GSK